Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8399520 | STEMLINE THERAP | Selective estrogen receptor modulator |
Dec, 2024
(7 months from now) | |
US7612114 | STEMLINE THERAP | Selective estrogen receptor modulator |
Aug, 2026
(2 years from now) | |
US10385008 | STEMLINE THERAP | Polymorphic forms of RAD1901-2HCL |
Jan, 2038
(13 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10071066 | STEMLINE THERAP | Method of treating cancer using selective estrogen receptor modulators |
Oct, 2034
(10 years from now) | |
US10420734 | STEMLINE THERAP | Method of treating cancer using selective estrogen receptor modulators |
Oct, 2034
(10 years from now) | |
US11779552 | STEMLINE THERAP | Method of treating cancer using selective estrogen receptor modulators |
Oct, 2034
(10 years from now) | |
US11819480 | STEMLINE THERAP | Methods for treating cancer |
Nov, 2036
(12 years from now) | |
US10745343 | STEMLINE THERAP | Polymorphic forms of RAD1901-2HCl |
Jan, 2038
(13 years from now) |
Orserdu is owned by Stemline Therap.
Orserdu contains Elacestrant Dihydrochloride.
Orserdu has a total of 8 drug patents out of which 0 drug patents have expired.
Orserdu was authorised for market use on 27 January, 2023.
Orserdu is available in tablet;oral dosage forms.
Orserdu can be used as treatment of an er-positive breast cancer, treatment of an er-positive breast cancer following at least one line of endocrine therapy.
Drug patent challenges can be filed against Orserdu from 27 January, 2027.
The generics of Orserdu are possible to be released after 05 January, 2038.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jan 27, 2028 |
Drugs and Companies using ELACESTRANT DIHYDROCHLORIDE ingredient
NCE-1 date: 27 January, 2027
Market Authorisation Date: 27 January, 2023
Treatment: Treatment of an er-positive breast cancer following at least one line of endocrine therapy; Treatment of an er-positive breast cancer
Dosage: TABLET;ORAL